Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19A and Olverembatinib in Newly Diagnosed Ph+ ALL
NCT07074496Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2024
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of thiscart19a and olverembatinib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Complete Molecular Remission at 3 months and Adverse Events at 2 years. Started Jan 2024; status: recruiting.
02
Drugs
thiscart19aolverembatinib
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT07074496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07074496.